Published in

Wiley, Small, 18(6), p. 2041-2049, 2010

DOI: 10.1002/smll.201000596

Links

Tools

Export citation

Search in Google Scholar

A Light-activated Theranostic Nanoagent for Targeted Macrophage Ablation in Inflammatory Atherosclerosis

Journal article published in 2010 by Jason R. McCarthy, Ethan Korngold, Ralph Weissleder ORCID, Farouc A. Jaffer
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The synthesis and utility of a multimodal theranostic nanoagent based upon magnetofluorescent nanoparticles for the treatment of inflammatory atherosclerosis is described. These particles are modified with near-infrared fluorophores and light-activated therapeutic moieties, which allow for the optical determination of agent localization and phototoxic activation at spectrally distinct wavelengths. The resulting agent is readily taken up by murine macrophages in vitro, and is highly phototoxic, with an LD50 of 430 pM. Intravenous administration results in the localization of the nanoagent within macrophage-rich atherosclerotic lesions that can be imaged by intravital fluorescence microscopy. Irradiation of the atheroma with 650 nm light in order to activate the therapeutic component results in eradication of inflammatory macrophages, which may induce lesion stabilization. Importantly, these agents display limited skin photosensitivity, are highly efficacious, and provide an integrated imaging and therapeutic nanoplatform for atherosclerosis.